Loading
Lexeo Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by CHOLMONDELEY PAULA H, was filed 26 Nov 2024.
Lexeo Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Lexeo Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 23 October 2026, brought 28 filings signed by 11 insiders.
The flow runs one way only: 11 sales worth €468k, from 6 insiders, and no purchase. Townsend Richard Nolan filed the largest sale, €271k, on 7 April 2026.
With 28 filings in twelve months, the company is more active than the median of 24 filings across the 3,168 companies we follow on the same exchange. The full history, which starts in 2023, counts 3 purchases against 47 sales.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
104
Thresholds
n/a
Buy Volume
€7M
3 ops. · all time
Sell Volume
€2M
47 ops. · all time
Who traded when
BuySaleRichard Nolan Townsend11 sales
Jose Manuel Otero7 sales
Adler Eric6 sales
Robertson Jenny6 sales
Tai Sandi See6 sales
Cholmondeley Paula H1 buy
+1 other insider
Since the insiders bought
- +25.9%Entry US$7.83 · Close at T+365 US$9.86
- -26.3%Entry US$10.78 · Close at T+365 US$7.95
- -26.3%Entry US$10.78 · Close at T+365 US$7.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.02
Analyst consensus
10 analysts1.20/5
US$9.00Target US$20.30(+572%)US$30.00
Income statement
RevenueUS$563.1k
EBITDA-US$97.7M-17346% margin
Net income-US$100M0.0% margin
Valuation
PER (forward)-2.2x
P/Book1.0x
Beta1.64
Balance sheet & cash
Market capUS$247.9M
Total debtUS$7.9M
Free Cash Flow-US$99M
Debt / Equity3%
Profitability & ownership
ROE-46.8%
ROA-27.6%
% insiders0.6%
% institutions114.8%
Last declaration on 28 September 2026
Declarations104 total
2,306 shares@ US$2.6440.0022% mcap0.9% of flowCommon StockSEC:0001995218-26-000017:0
2,110 shares@ US$2.6440.0020% mcap4.8% of flowCommon StockSEC:0002024096-26-000015:0
2,714 shares@ US$3.5790.0035% mcap8.8% of flowCommon StockSEC:0002109299-26-000009:0
1,304 shares@ US$4.95710.0023% mcap5.8% of flowCommon StockSEC:0002024096-26-000013:0
4,117 shares@ US$4.90710.0073% mcap48.8% of flowCommonSEC144:0001959173-26-006152
1,304 shares@ US$4.95710.0023% mcap5.8% of flowCommonSEC144:0001959173-26-006153
3,345 shares@ US$4.95120.0060% mcap2.5% of flowCommonSEC144:0001959173-26-006154
22,306 shares@ US$4.42410.036% mcap100.0% of flowCommonSEC144:0001959173-26-005032
25,947 shares@ US$4.47780.043% mcap17.6% of flowCommonSEC144:0001959173-26-005031
4,641 shares@ US$4.4850.0077% mcap51.2% of flowCommonSEC144:0001959173-26-005033
4,666 shares@ US$4.48330.0077% mcap19.1% of flowCommonSEC144:0001959173-26-005036
22,306 shares@ US$4.4247.7% of flowCommon StockSEC:0002109299-26-000007:1
55,000 sharesCommon StockSEC:0002109299-26-000007:0
55,000 shares@ US$5.693446.8% of flowCommon StockSEC:0001995218-26-000009:0
2,623 shares@ US$2.6441.0% of flowCommon StockSEC:0001995218-26-000006:0
5,930 shares@ US$2.64414.2% of flowCommon StockSEC:0002024096-26-000007:0
3,016 shares@ US$6.397216.9% of flowCommon StockSEC:0002024096-26-000005:0
721 shares@ US$9.276.0% of flowCommon StockSEC:0002024096-26-000004:0
10,173 shares@ US$6.3829.5% of flowCommon StockSEC:0001995218-26-000004:0
49,500 shares0Common StockSEC:0002109299-26-000004:0
65,000 shares0Common StockSEC:0002024096-26-000002:0
161,665 shares0Common StockSEC:0001995218-26-000002:0
44,665 shares0Common StockSEC:0002083206-26-000002:0
386 shares@ US$9.2712.1% of flowCommon StockSEC:0002009350-25-000005:0
721 shares@ US$9.276.0% of flowCommon StockSEC:0002024096-25-000005:0
25 of 104 declarations
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a company focused on developing gene therapies for rare genetic diseases. It emphasizes innovation in DNA-based treatment solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
